Connaughton Bernadette 4

What Happened
Bernadette Connaughton, a director of Halozyme Therapeutics (HALO), sold 1,625 shares in an open-market transaction on May 1, 2026 at $63.48 per share, for total proceeds of approximately $103,155. This was a sale (not a purchase or option exercise), which is commonly routine for insiders.

Key Details

• Transaction date: May 1, 2026; Price: $63.48 per share; Shares sold: 1,625; Total value: ~$103,155.
• Transaction type: Sale (code S) — reported as an open market or private sale.
• Filing date / accession: Form 4 filed May 5, 2026 (reporting period 2026-05-01); filing appears timely.
• Shares owned after transaction: Not disclosed in the information provided on this summary.
• Footnote: The sale was made pursuant to a written Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2025 (prearranged trading plan).

Context
Sales made under Rule 10b5-1 plans are preplanned and often routine (e.g., for diversification or liquidity) and therefore do not necessarily signal the director’s current view of the company’s prospects. This single sale does not by itself indicate a change in company fundamentals; retail investors should consider insider activity alongside other signals and company-specific news.